AEZS~ A Potential Breakthrough in Cancer Therapy Product ? New Chemical Entity (NCE) composed of a targeted synthetic peptide carrier linked to doxorubicin ? Value proposition: Improved, targeted delivery of doxorubicin with improved benefit -risk profile Status ?ZoptEC Phase 3 trial in endometrial cancer –Fully enrolled (over 500 patients) / over 120 active sites in North America, Europe and Israel –CRO Ergomed to assume 30% up to $10 million of clinical and reg. costs –1st Interim Results: DSMB recommendation to continue ZoptECtrial, April 2015 –2nd Interim Results: Expected October 2015
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.